Ampio Pharmaceuticals Company Profile (NYSEMKT:AMPE)

About Ampio Pharmaceuticals (NYSEMKT:AMPE)

Ampio Pharmaceuticals logoAmpio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company's two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA). Optina is a low-dose formulation of danazol. The Ampio segment consists of its biopharmaceuticals compounds and the clinical trials associated with them. The Company is primarily developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process, and decreasing vascular permeability.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSEMKT:AMPE
  • CUSIP: 03209T10
  • Web: ampiopharma.com/
Capitalization:
  • Market Cap: $31.2 million
  • Outstanding Shares: 57,242,000
Average Prices:
  • 50 Day Moving Avg: $0.57
  • 200 Day Moving Avg: $0.76
  • 52 Week Range: $0.47 - $1.14
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.87
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.09 per share
  • Price / Book: 6.19
Profitability:
  • EBIDTA: ($12,450,000.00)
  • Return on Equity: -131.07%
  • Return on Assets: -62.52%
Misc:
  • Average Volume: 505,325 shs.
  • Short Ratio: 15.12
 

Frequently Asked Questions for Ampio Pharmaceuticals (NYSEMKT:AMPE)

What is Ampio Pharmaceuticals' stock symbol?

Ampio Pharmaceuticals trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "AMPE."

How were Ampio Pharmaceuticals' earnings last quarter?

Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) issued its quarterly earnings data on Tuesday, February, 24th. The company reported ($0.19) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.20) by $0.01. View Ampio Pharmaceuticals' Earnings History.

Who are some of Ampio Pharmaceuticals' key competitors?

Who are Ampio Pharmaceuticals' key executives?

Ampio Pharmaceuticals' management team includes the folowing people:

  • Michael Macaluso, Chairman of the Board, Chief Executive Officer
  • Thomas E. Chilcott III, Interim Chief Financial Officer
  • David Bar-Or M.D., Chief Scientific Officer, Director
  • Gregory A. Gould CPA, Treasurer, Secretary
  • Vaughan Lennox Clift M.D., Chief Regulatory Affairs Officer
  • Philip H. Coelho M.D., Independent Director
  • Richard B. Giles, Independent Director
  • David R. Stevens Ph.D., Independent Director

How do I buy Ampio Pharmaceuticals stock?

Shares of Ampio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ampio Pharmaceuticals' stock price today?

One share of Ampio Pharmaceuticals stock can currently be purchased for approximately $0.55.


MarketBeat Community Rating for Ampio Pharmaceuticals (NYSEMKT AMPE)
Community Ranking:  3.9 out of 5 (  )
Outperform Votes:  35 (Vote Outperform)
Underperform Votes:  10 (Vote Underperform)
Total Votes:  45
MarketBeat's community ratings are surveys of what our community members think about Ampio Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ampio Pharmaceuticals (NYSEMKT:AMPE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Ampio Pharmaceuticals (NYSEMKT:AMPE)
Show:
DateFirmActionRatingPrice TargetDetails
6/30/2016Janney Montgomery ScottReiterated RatingPositiveView Rating Details
(Data available from 7/21/2015 forward)

Earnings

Earnings History for Ampio Pharmaceuticals (NYSEMKT:AMPE)
Earnings by Quarter for Ampio Pharmaceuticals (NYSEMKT:AMPE)
Earnings History by Quarter for Ampio Pharmaceuticals (NYSEMKT AMPE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/24/2015($0.20)($0.19)ViewN/AView Earnings Details
11/12/2014($0.17)($0.18)ViewN/AView Earnings Details
8/12/2014($0.24)($0.17)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ampio Pharmaceuticals (NYSEMKT:AMPE)
Current Year EPS Consensus Estimate: $-0.610 EPS
Next Year EPS Consensus Estimate: $-0.190 EPS

Dividends

Dividend History for Ampio Pharmaceuticals (NYSEMKT:AMPE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ampio Pharmaceuticals (NYSEMKT:AMPE)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Ampio Pharmaceuticals (NYSEMKT:AMPE)
Latest Headlines for Ampio Pharmaceuticals (NYSEMKT:AMPE)
Source:
DateHeadline
finance.yahoo.com logoAmpio Hosting Conference Call, Wednesday, July 12, 4:30 pm EDT
finance.yahoo.com - July 6 at 5:09 PM
streetinsider.com logoAmpio Pharma (AMPE) Begins Dosing in Final Pivotal Clinical Trial for Ampion BLA
www.streetinsider.com - June 23 at 4:06 PM
finance.yahoo.com logoAmpio Injects First Patient in Final Pivotal Clinical Trial for Ampion™ BLA
finance.yahoo.com - June 22 at 12:18 PM
finance.yahoo.com logoAmpio Announces Appointment of Interim Chief Financial Officer
finance.yahoo.com - June 12 at 4:34 PM
finance.yahoo.com logoAmpio Pharmaceuticals, Inc. Announces Closing of Registered Direct Offering
finance.yahoo.com - June 7 at 8:41 PM
streetinsider.com logoAmpio Pharma (AMPE) Says Human Macrophage Study Results Accepted for Presentation at AAST Meeting
www.streetinsider.com - May 6 at 1:33 AM
finance.yahoo.com logoAmpion™ Human Macrophage Study Results Accepted for Presentation at the 2017 Annual AAST Meeting in Baltimore
finance.yahoo.com - May 5 at 3:31 PM
finance.yahoo.com logoAmpio Initiates Pivotal Trial of Ampion™
finance.yahoo.com - May 1 at 9:38 AM
us.rd.yahoo.com logoAmpio Pharmaceuticals Amends Warrant Agreement
us.rd.yahoo.com - March 28 at 9:31 AM
biz.yahoo.com logoAMPIO PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
biz.yahoo.com - March 28 at 9:31 AM
us.rd.yahoo.com logoAmpio Updates Intellectual Property and Regulatory Exclusivity Strategy to Support the Commercialization of Ampion™
us.rd.yahoo.com - March 23 at 11:14 PM
streetinsider.com logoAmpio Pharma (AMPE) Announces Issuance of China Patent - StreetInsider.com
www.streetinsider.com - March 23 at 3:45 PM
bizjournals.com logoColorado biotech's accountants express 'substantial doubt' about firm's future
www.bizjournals.com - March 23 at 3:45 PM
us.rd.yahoo.com logoUpdate - Ampio Pharmaceuticals Provides Corporate Update
us.rd.yahoo.com - March 22 at 8:34 PM
streetinsider.com logoAmpio Pharma (AMPE) Provides Corporate Update; Locust Walk to Serve as Strategic Advisor - StreetInsider.com
www.streetinsider.com - March 21 at 3:54 PM
us.rd.yahoo.com logoAmpio Pharmaceuticals Provides Corporate Update
us.rd.yahoo.com - March 20 at 3:50 PM
prnewswire.com logoAmpio Hosting Conference Call Tuesday, March 7, 4:30pm EST - PR Newswire (press release)
www.prnewswire.com - March 1 at 8:12 AM
finance.yahoo.com logoAmpio Hosting Conference Call Tuesday, March 7, 4:30pm EST
finance.yahoo.com - March 1 at 8:12 AM
bizjournals.com logoColorado biotech's drug for knee pain shows a 'promising effect'
www.bizjournals.com - February 28 at 9:22 AM
finance.yahoo.com logoAmpio Receives Guidance from the FDA and Proposes a Path for Approval for Single-Injection Ampion™ for …
finance.yahoo.com - February 28 at 9:22 AM
us.rd.yahoo.com logoAmpio Receives Guidance from the FDA and Proposes a Path for Approval for Single-Injection Ampion™ for the Treatment of Pain Due to Severe Osteoarthritis of the Knee
us.rd.yahoo.com - February 28 at 9:22 AM
us.rd.yahoo.com logo8:31 am Ampio Pharma announcs that the Office of Tissue & Advanced Therapies has recently provided additional guidance for the path to approval of Ampion as a treatment for pain due to severe Osteoarthritis of the knee
us.rd.yahoo.com - February 28 at 9:22 AM
streetinsider.com logoAmpio Pharma (AMPE) Receives Guidance from the FDA on Ampion - StreetInsider.com
www.streetinsider.com - February 27 at 3:38 PM
seekingalpha.com logoAmpio Pharmaceuticals - Running On Fumes
seekingalpha.com - February 2 at 2:12 AM

Social

This page was last updated on 7/21/2017 by MarketBeat.com Staff